Access brought to you by: LOCKSS
Login
Tofacitinib: Phase 3 Studies of 1 to 2 Year Duration—ORAL Sync, Standard, and Scan
DMARD=disease-modifying antirheumatic drug; IR=nonresponder; MTX=methotrexate.
Reproduced with permission from IB McInnes, PhD.
Thank you for your interest in spreading the word on MD Conference Express.
NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.